文献速递核素与放射性配体治疗肿瘤 PET/CT

内脏转移预测177Lu-PSMA放射性配体治疗去势抵抗性前列腺癌的疗效与生存:系统综述与荟萃分析

Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Nucl Med · 2020-01-01

结果显示,内脏转移不仅预测较低的生化反应率(汇总单变量OR 0.38,95%CI 0.22-0.66),还是无进展生存期和总生存期较差的显著预后因素。

要点

  • 内脏转移预测177Lu-PSMA RLT后较低的生化反应率(OR 0.38,95%CI 0.22-0.66)。
  • 内脏转移与较差的无进展生存期显著相关(多变量HR 1.48,95%CI 1.15-1.92)。
  • 内脏转移与较差的总生存期显著相关(多变量HR 2.22,95%CI 1.82-2.70)。

核心结论

  • 在mCRPC患者中,内脏转移与177Lu-PSMA RLT治疗后较差的生化反应和生存结局相关。

主要发现

  • 内脏转移预测较低的生化反应率(汇总单变量OR 0.38,95%CI 0.22-0.66)。
  • 内脏转移是较差无进展生存期的显著预后因素(汇总单变量HR 1.85,95%CI 1.39-2.46;多变量HR 1.48,95%CI 1.15-1.92)。
  • 内脏转移是较差总生存期的显著预后因素(汇总单变量HR 1.77,95%CI 1.29-2.44;多变量HR 2.22,95%CI 1.82-2.70)。
  • 未发现发表偏倚的证据。

临床怎么用

  • 内脏转移可作为mCRPC患者接受177Lu-PSMA RLT前风险分层的重要指标。
  • 该结果有助于指导此类患者优化治疗策略的选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The presence of visceral metastases is associated with poor prognosis in patients of metastatic castration-resistant prostate cancer (mCRPC) treated with hormonal therapy and chemotherapy. However, studies evaluating its impact on treatment outcomes with Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) are currently limited and show inconsistent results. This systematic review was conducted to precisely evaluate the impact of visceral metastases on biochemical response and survival outcomes in patients of mCRPC treated with Lu-PSMA RLT. METHODS: This systematic review followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines. Searches in PubMed, Scopus, and EMBASE were made using relevant keywords, and articles up to May 2020 were included. Univariate and multivariate odds ratios and hazard ratios (HRs) were extracted from the individual articles, and pooled estimates were generated using meta-analysis. RESULTS: Twelve articles comprising 1504 patients were included in this review. Presence of visceral metastases not only predicted low biochemical response rate (pooled univariate odds ratio: 0.38, 95% confidence interval [CI], 0.22-0.66) but was also a significant prognosticator of worse progression-free survival (pooled univariate HR, 1.85; 95% CI, 1.39-2.46; and pooled multivariate HR, 1.48; 95% CI, 1.15-1.92) and overall survival (pooled univariate HR, 1.77; 95% CI, 1.29-2.44; and pooled multivariate HR, 2.22; 95% CI, 1.82-2.70). There was no evidence of publication bias. CONCLUSIONS: Presence of visceral metastases was associated with poor response and survival outcomes in patients of mCRPC treated with Lu-PSMA RLT. The results are clinically significant for pretreatment risk stratification of such patients and to guide optimal treatment strategies.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Satapathy S, Mittal BR, Sood A, et al. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis. Clin Nucl Med. 2020. PMID: 32956129. doi:10.1097/RLU.0000000000003307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。